ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements
Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.
Virinchi Ltd reported revenue from operations of ₹73.9 Cr (+19.6% YoY) and a net loss of ₹19.5 Cr for Q2 FY27.
Virinchi scheduled a board meeting for November 10, 2026 to consider a fund raise, a shareholder approval process and quarterly results. Fund raise requires shareholder approval.
The company filed its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialization activities for the quarter ending September 30, 2026.
Virinchi Ltd. held its 37th Annual General Meeting on September 30, 2026. Shareholders adopted financial statements and approved the re-appointment of a director.
Virinchi Ltd has dispatched letters to shareholders with the weblink for the Annual Report for FY 2025-26, in compliance with SEBI Listing Regulations.
Virinchi Limited has issued a notice for its 37th Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.
Virinchi Ltd submitted its Annual Report and notice for the 37th AGM scheduled on September 30, 2026, to the stock exchanges.
Virinchi Ltd announced the outcome of its board meeting, including the date for its 37th Annual General Meeting and the reappointment of a director.
Virinchi Ltd reported revenue from operations of ₹70.1 Cr (-12.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.
Virinchi Ltd announced voting results for a postal ballot approving the acquisition of a healthcare business division from its subsidiary, Virinchi Health Care Private Limited.
Virinchi Ltd shareholders approved the slump sale acquisition of the Bristlecone Hospitals business division from its material subsidiary, Virinchi Health Care Private Limited, via postal ballot.
Virinchi Ltd has scheduled a board meeting for August 13, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Virinchi Limited announced the approval of postal ballot resolutions. Shareholders approved loans under Section 185 and material related party transactions with Virinchi Health Care and Vivo Bio Tech.
Virinchi Limited filed revised XBRL financials for FY26 to correct EPS and PAT mismatches. The revisions follow an NSE clarification request dated June 25, 2026.
Virinchi Ltd seeks shareholder approval via postal ballot to acquire its healthcare division for Rs.100 Crore. Voting runs from July 12 to August 10, 2026.
Virinchi Limited approved a slump sale acquisition of its subsidiary's healthcare division. The unit reported ₹82.99 Crore turnover, with completion expected by August 2026.
Virinchi Limited approved the acquisition of Bristlecone Hospitals' healthcare division for Rs.100 Crore. The transaction will be executed via a slump sale from its material subsidiary.
Virinchi Ltd issued a postal ballot notice for shareholder approval on loans to subsidiary and material related party transactions. The outcome will be announced by July 16, 2026.
Virinchi Limited allotted 1,50,000 equity shares following the conversion of warrants at Rs. 25 per share. This exercise increases the company's paid-up equity capital.
Virinchi Limited allotted 20,00,000 equity shares following the conversion of warrants at ₹25 per share. The ₹5 Crore transaction increases the company's total paid-up share capital.
Virinchi Limited reported consolidated FY26 revenue of ₹286.13 Crore. Profitability was impacted by a one-time ₹8.43 Crore bad-debt write-off despite 20% growth in SaaS revenue.
Virinchi Ltd reported revenue from operations of ₹66 Cr (-4.2% YoY) and a net loss of ₹15.7 Cr for Q4 FY26.
Virinchi Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The board approved these results in their May 28 meeting.
Virinchi Limited scheduled a board meeting on May 28, 2026, to approve audited financial results. Trading window remains closed for designated persons until May 30.
Virinchi Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor noted a minor one-day disclosure delay resulting in an NSE warning letter.
Virinchi Limited allotted 8,50,000 equity shares at Rs. 28 per share following the conversion of warrants. The total transaction value is ₹2.38 Crore. This conversion increases the company's paid-up share capital to 10,96,46,896 shares.
Virinchi Limited allotted 8,50,000 equity shares to promoter group entity Vivo Bio Tech Limited following the conversion of warrants. The allotment occurred at an issue price of Rs.28 per share, with Rs.1.78 Crore received as application money. This transaction increases the company's total issued share capital to 10,96,46,896 equity shares.
Virinchi Limited submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate from Aarthi Consultants confirms the processing of dematerialization requests and cancellation of physical share certificates within the mandated timelines. This is a routine administrative filing.